AMILI’s Series A funding round aims to accelerate the company’s business expansion in Southeast Asia and wider Asia subsequently.
AMILI, Singapore-based precision gut microbiome company, announced today that it has raised US$10.5 million in its Series A round.
The funding round was led by Vulcan Capital, with new investors including Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code and SEEDS Capital, the investment arm of Enterprise Singapore amongst others.
